drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
A biologic monoclonal antibody designed as an immune-checkpoint agonist targeting PSGL-1 on T cells. It aims to selectively attenuate chronically activated effector/memory T cells via activation-induced cell death and dampening of TCR-driven signaling, reducing proinflammatory cytokine production; administered subcutaneously in single- and multiple-ascending doses.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Monoclonal
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Monoclonal antibody agonist of the immune checkpoint PSGL-1 on T cells that triggers inhibitory signaling to selectively attenuate chronically activated effector/memory T cells, inducing activation‑induced cell death and dampening TCR-driven signaling, thereby reducing proinflammatory cytokine production while sparing resting/naive T cells.
drug_name
ALTB-268
nct_id_drug_ref
NCT05723692